Ronan J Kelly, Blair V Landon, Ali H Zaidi, Dipika Singh, Jenna V Canzoniero, Archana Balan, Russell K Hales, K Ranh Voong, Richard J Battafarano, Blair A Jobe, Stephen C Yang, Stephen Broderick, Jinny Ha, Kristen A Marrone, Gavin Pereira, Nisha Rao, Aryan Borole, Katerina Karaindrou, Zineb Belcaid, James R White, Suqi Ke, Ali I Amjad, Benny Weksler, Eun Ji Shin, Elizabeth Thompson, Kellie N Smith, Drew M Pardoll, Chen Hu, Josephine L Feliciano, Valsamo Anagnostou, Vincent K Lam
Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy responses for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab-relatlimab (Arm B, n = 16) in combination with chemoradiotherapy in 32 patients with resectable stage II/stage III gastroesophageal cancer together with an in-depth evaluation of pathological, molecular and functional immune responses...
March 19, 2024: Nature Medicine